Questran Related Published Studies
Well-designed clinical trials related to Questran (Cholestyramine)
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. [2011.05]
Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability. [2011.03]
The effect of gemfibrozil, niacin and cholestyramine combination therapy on
metabolic syndrome in the Armed Forces Regression Study. [2011]
The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. [2010.10]
Low doses of cholestyramine in the treatment of hyperthyroidism. [2008.12]
Low doses of cholestyramine in the treatment of hyperthyroidism. [2008.10.23]
Low doses of cholestyramine in the treatment of hyperthyroidism. [2008.08]
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]
Atovaquone plus cholestyramine in patients coinfected with Babesia microti and Borrelia burgdorferi refractory to other treatment. [2006.01]
The effect of cholesterol reduction with cholestyramine on renal function. [2005.11]
Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. [2005.09]
The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. [2005.05]
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. [2004.11]
Dose-dependent efficacy of diclofenac-cholestyramine on pain and periarticular ossifications after total hip arthroplasty: a double-blind, prospective, randomised trial. [2004.09]
DEAE-Dextran in the treatment of primary hypercholesterolemia and/or hypercholesterolemia combined with hypertriglyceridemia. A multicentric randomized study on the efficacy of DEAE-Dextran compared with Cholestyramine. [2003.07]
Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. [2001.01.05]
Effects of cholestyramine on vitamin E levels in patients treated with statins. [2000.12]
Effect of resin surface charge on gastric mucoadhesion and residence of cholestyramine. [2000.09.15]
Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. [1999.06]
Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study). [1998.06]
Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. [1998.05]
Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. [1998.03]
The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. [1998.02]
Concomitant administration of cholestyramine influences the absorption of troglitazone. [1998.01]
Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. [1997.09.15]
Cholestyramine influences meal-stimulated pancreaticobiliary function and plasma cholecystokinin independent of gastric emptying and food digestion. [1997.08]
Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. [1997.02]
Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. [1996.09]
Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. [1996.07]
[Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia] [1996.05.25]
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. [1995.11]
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. [1995.11]
Effects of cholestyramine on gallbladder and gastric emptying in obese and lean subjects. [1995.10]
Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. [1995.07.13]
The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. [1995]
Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia. [1994.11]
Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. [1994.09.15]
The effect of colestipol and cholestyramine on ibuprofen bioavailability in man. [1994.08]
The effects of cholestyramine and colestipol on the absorption of diclofenac in man. [1994.08]
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. [1994.05]
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. [1994.04.01]
Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. [1994]
Well-designed clinical trials possibly related to Questran (Cholestyramine)
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. [2010.12]
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study. [2010.12]
The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. [2010.08.03]
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. [2010.06]
A simple high-performance liquid chromatographic method for the determination of diclofenac in human plasma: application to a comparative bioavailability study. [2009.02]
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. [2009]
Interventions for treating lymphocytic colitis. [2008.04.16]
The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. [2007.07]
Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. [2007.02]
Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. [2006.12]
Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. [2006.09]
Diet, lifestyle, and nonstatin trials: review of time to benefit. [2005.09.05]
Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study. [2005.03]
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. [2005.01.18]
Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. [2004.08]
No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty. [2004.02]
Natural history of pruritus in primary biliary cirrhosis. [2003.07]
Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2 diabetes. [2002.05]
The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. [2002]
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. [2001.11.27]
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. [2001.10]
Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. [2001.07.24]
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. [2001.02]
Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. [2001.02]
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). [2000.12.15]
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. [2000.09]
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. [2000.03]
The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. [1999.10]
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study] [1999.08]
[Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS] [1999.04]
Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment. [1998.08.27]
The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. [1998.06.22]
Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group. [1998.01]
Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study. [1998.01]
Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. [1997.09]
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). [1997.08.01]
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. [1996.12]
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. [1996.10.01]
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. [1996.09.06]
Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. [1995.10]
Potential role of raising dietary protein intake for reducing risk of atherosclerosis. [1995.10]
Relationships between nutrient intake and progression/regression of coronary atherosclerosis as assessed by serial quantitative angiography. [1995.10]
Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. [1995.10]
Changes in dietary fat intake preceding the diagnosis of cancer. [1995.09]
Probucol treatment decreases serum concentrations of diet-derived antioxidants. [1995.08]
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. [1995.08]
Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database. [1995.07.13]
The acceptability of resin therapy to patients attending a hospital lipid clinic. [1995.07]
Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults. [1995.07]
Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. [1995.07]
Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome. [1995.06]
Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. [1995.04.01]
Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. [1995.03]
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. [1995.02.23]
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). [1994.11.01]
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. [1994.10.29]
The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patients. [1994.08]
Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. [1994.05.26]
Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment. [1994.05.26]
|
